Biogen Inc. (NASDAQ:BIIB) is a leading biotechnology company known for its focus on neurological diseases. The company develops therapies for conditions like multiple sclerosis and Alzheimer's disease. Biogen competes with other biotech firms such as Amgen and Roche. Recently, Evan Seigerman from BMO Capital set a price target of $196 for Biogen, while the stock was trading at $201.18.
The price target was increased from a previous target of $165, as highlighted by TheFly. This adjustment reflects a positive outlook on Biogen's performance. The stock's current price of $201.18 is approximately 2.57% above the new target, indicating investor confidence. The stock has seen an 8.53% increase, with a change of $15.82, showcasing strong market activity.
Biogen's recent Q4 2025 earnings call, as reported by Seeking Alpha, provided valuable insights into the company's financial health. The call likely covered revenue, profit margins, and strategic initiatives. Such earnings calls are crucial for investors to gauge the company's market position and future prospects.
The stock's price today fluctuated between $184.60 and $202.41, with $202.41 marking its highest price over the past year. The lowest price in the past year was $110.04, indicating significant growth. Biogen's market capitalization stands at approximately $29.51 billion, reflecting its substantial presence in the biotech industry.
The trading volume for the day is 3,404,217 shares, highlighting active investor interest. This level of trading activity on the NASDAQ exchange underscores the market's attention to Biogen's performance and potential.
